U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

The Victoria, B.C.-based company is developing EP-104IAR for osteoarthritis pain and a new formulation for eosinophilic ...

CNW/ - (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced its financial results for the quarter ended June 30, ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.

Clarius Group LLC upped its Regeneron stake by 82.1% last quarter, gobbling up 509 extra shares like they were on clearance. This boosted their total to 1,129 shares, worth a neat $716,000, showing ...

Institutional investors now control a whopping 83.31% of Regeneron’s stock, painting a picture of trust in the company’s long-term prospects—even if short-term numbers aren’t turning heads. However, ...

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported first-quarter profit of $808.7 million. The Tarrytown, New York-based company said it had profit ...